5Kimura M,Yamagishi Y,Kawasumi N,et al.Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene.Jpn J Antibiot,2010,63 (3):255-264.
6Chu HY,Jain R,Xie H,et al.Voriconazole therapeutic drug monitoring:retrospective cohort study of the relationship to clinical outcomes and adverse events.BMC Infect Dis,2013,13(1):105.
7Neely M,Rushing T,Kovacs A,et al.Voriconazole pharmacokinetics and pharmacodynamics in children.Clin Infect Dis,2010,50(1):27-36.
8Mitsani D,Nguyen MH,Shields RK,et al.Prospective,observational study of voriconazole therapeutic drug monitoring among lung transplant recipientsreceiving prophylaxis:factors impacting levels of and associations between serum troughs,efficacy,and toxicity.Antimicrob Agents Chemother,2012,56 (5):2371-2377.
9Gorski E,Esterly JS,Postelnick M,et al.Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections.Antimicrob Agents Chemother,2011,55 (1):184-189.
10Belaiche S,Roustit M,Bedouch P,et al.Management of voriconazole hepatotoxicity in a lung transplant patient.Transpl Infect Dis,2011,13(3):309-311.
6PFALLER MA,ZHANG J,MESSER SA,et al. In vitro activities of voriconazole, ftubonazol,and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother, 1999,43 ( 1 ) : 169 - 171.
7SUTTON DA, SANCHE SE, REVANKAR SG, et al. In vitro amplhoteriein B resistance in clinical isolates of Aspergillus terreus,with a head-to-head comparison to voriconazole. J ClinMicro2biol, 1999,37 (7) :2343.
8DENNING DW,R IBAUD P,MILP IED N,et al. Efficacy and safety of vorieonazole in the treatment of acute invasive aspergillosis. Clin Infect Dis,2002,34(5) :563-571.
9Yanni SB,Annaert PP,AugustijnsP,etal.Roleofflavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes[J].Drug Metab Dispos,2008; 36:1119-1125.
10Xiao ZS,Goldstein JA,Xie HG,et al.Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and identification of a new rare CYP2C19 mutant allele[J].J Pharnacol Experi Ther,1997; 281:604-609.
5Vieira MA,Cavalcanti Mdo A,Costa DL,et al.Visual evoked potentials show strong positive association with intracranial pressure in patients with cryptococcal meningitis[J].Arq Neuropsiquiatr,2015,73(4):309-313.
6Selvan LD,Sreenivasamurthy SK,Kumar S,et al.Characterization of host response to Cryptococcus neoformans through quantitative proteomic analysis of cryptococcal meningitis coinfected with HIV[J].Mol Biosyst,2015,11(9):2529-2540.
